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Diabetes has been identiﬁed as an important risk factor for infection. But relatively little is known about how
diabetes alters the inﬂammatory response to bacteria. The objective of this study was to investigate how diabetes
affects host–bacteria interactions by focusing on the inﬂammatory response in a connective tissue setting.
Diabetic (db/db) and control (db/þ ) mice were inoculated with Porphyromonas gingivalis, a pathogen associated
with bite wounds and periodontal disease. The response was measured histologically or by the expression of
inﬂammatory cytokines. By quantitative histologic analysis, there was little difference between the diabetic and
control mice on day 1. On day 3, however, the inﬂammatory inﬁltrate had subsided in the control group, whereas it
had not in the diabetic group (po0.05). Similar results were noted at the molecular level by the persistent
expression of tumor necrosis factor-a (TNF-a) and the chemokines MCP-1 and MIP-2. The importance of TNF in this
process was demonstrated by reversal of the prolonged chemokine expression by speciﬁc inhibition of TNF with
Enbrel. These results indicate that cytokine dysregulation associated with prolonged TNF expression represents a
mechanism through which bacteria may induce a more damaging inﬂammatory response in diabetic individuals.
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Diabetes mellitus affects over 15 million Americans and has
a dramatic impact on health, causing a high degree of
morbidity and mortality in affected individuals as well as
placing an economic burden on the health care system
(Edelman, 1998; Zimmet et al, 2001) Although type 1 and
type 2 diabetes have different etiologies, they share
common symptoms of glucose intolerance, hyperglycemia,
hyperlipidemia, and many of the same complications. (Kahn
and Flier, 2000). As the course of diabetes progresses,
complications develop, which include a number of vascular
abnormalities, nephropathy, poor wound healing, and
enhanced risk of infection (Jensen and Deckert, 1992;
Libman et al, 1993; Loe, 1993; Elner et al, 1995; Patterson
and Andriole, 1997; Vlassara and Palace, 2002).
Several mechanisms have been suggested for increased
susceptibility to infection in diabetics including impaired
chemotactic, phagocytic, and bacterial killing by cells of the
innate immune response (Drachman et al, 1966; Mowat and
Baum, 1971; Sima et al, 1988; Pickup and Crook, 1998).
Interestingly, diabetics are not more susceptible to all
infections but seem to be particularly more vulnerable to
Gram-negative infections (Joshi et al, 1999). These may
include urinary tract infections, soft-tissue infections, and
periodontal disease (Loe, 1993; Patterson and Andriole,
1997; Cutler et al, 1999; Joshi et al, 1999). Soft-tissue
infections, especially those associated with human or
animal bites may involve Gram-negative oral pathogens,
as does periodontitis (Williams, 1990; Goldstein, 1992;
Brook, 2003). Anaerobic bacteria are present in approxi-
mately one-third of bite wounds and are associated with the
formation of abscesses and with relatively serious infections
(Goldstein, 1992; Brook, 2003). In addition, enhanced sus-
ceptibility to periodontal pathogens is one of the significant
and characteristic complications of diabetes (Loe, 1993;
Nishimura et al, 1998).
Type 2 diabetes is associated with higher serum levels
of inflammatory cytokines (tumor necrosis factor, TNF)
(Desfaits et al, 1998; Katsuki et al, 1998; Fernanadez-Real
et al, 2001; Mishima et al, 2001). This may be due to the
production of TNF in adipose tissue (Hotamisligil et al, 1995)
(Hotamisligil, 1994), the activity of advanced glycation end
products or enhanced cytokine production caused by
indirect effects of hyperinsulinemia or hyperglycemia (Soop
et al, 2002; Vlassara and Palace, 2002). In vitro studies have
been carried out to examine the effect of diabetes on the
response of leukocytes to inflammatory stimuli such as
lipopolysaccharide (LPS). The results, however, have been
inconsistent with some studies showing decreased expres-
sion of inflammatory cytokines, whereas others have shown
significantly enhanced expression (Kulseng et al, 1996; Salvi
et al, 1997; Desfaits et al, 1998; Geerlings et al, 2000;
Zykova et al, 2000).
Despite the high societal cost of diabetes, relatively little
is know about how type 2 diabetes alters the inflammatory
response to bacteria, particularly in dermal connective
tissue. To investigate this matter, we tested the response
of normal and diabetic (db/db) mice using a scalp model
that is well suited to study host–bacteria interactions in a
connective tissue setting (Zubery et al, 1998; Graves et al,Abbreviations: TNF, tumor necrosis factor
Copyright r 2004 by The Society for Investigative Dermatology, Inc.
87
2001; Jiang et al, 2002). Since bacterial infection can induce
destructive inflammation and diabetics are more prone to
infection, studies presented here are significant since they
suggest a mechanism through which diabetes may alter the
response to bacteria.
Results
Histologic analysis demonstrated that 1 d following inocu-
lation of Porphyromonas gingivalis (5  108 ), a severe
inflammatory infiltrate formed consisting largely of poly-
morphonuclear neutrophils and that there was evidence of
cellular necrosis (data not shown). On day 3, there was
relatively little inflammation in the control group at both the
center of the inflammatory infiltrate and in the peripheral
areas (Fig 1E–H ). In contrast, there was less resolution of
the inflammatory infiltrate in the diabetic mice (Fig 1A–D).
This was supported by quantitative analysis using a scale
of inflammation ranging from 0 to 9 (Fig 2). On day 1, the
diabetic and control animals had a similar degree of PMN
infiltration at both the center and peripheral areas (p40.05)
(Fig 2A). On day 3, the number of PMNs was reduced in the
control group, whereas levels in diabetic were significantly
higher at both the center and periphery (po0.05) (Fig 2B).
When a lower level of bacterial inoculum was used (1  108)
similar results were obtained. Significantly higher numbers
of PMNs were present in the diabetic group on day 3 at both
the center of the inflammatory infiltrate and at the periphery
po0.05 (Fig 2C).
The RNase protection assay was carried out to measure
the level of cytokine expression in vivo at the site of
bacterial inoculation. The results showed that P. gingivalis
stimulated TNF expression in both diabetic and control
animals, with the increase being similar in both groups at
day 1 (p40.05) (Fig 3). By day 3, TNF expression had
decreased considerably in the control mice but had not in
the diabetics (po0.05). A similar pattern was observed for
chemokine expression (Fig 4). Both MIP-2 and MCP-1 were
strongly induced by inoculation of bacteria. MIP-2 expres-
sion was similar in the diabetic and control groups at day
1 (p40.05). By day 3, the level of MIP-2 had decreased,
but was still higher in the diabetic compared with the
normoglycemic group (po0.05) (Fig 4). For MCP-1 the
levels were also similar in diabetic and normoglycemic mice
on day 1 (p40.05). On day 3, MCP-1 expression persisted
at a much higher level in the diabetic compared with control
mice (po0.05) (Fig 4).
To examine the functional significance of prolonged TNF
expression, the effect of specifically inhibiting its activity
was assessed by measuring chemokine expression. Three
days following bacterial inoculation, MCP-1 and MIP-2
levels were still higher than the zero time point (Fig 5). But
diabetic mice treated with TNF inhibitor had significantly
reduced levels of both MCP-1 and MIP-2 compared with
control diabetic mice treated with PBS (po0.05) (Fig 5).
Discussion
The stimulation of cells from the innate immune system
in diabetic and normal humans and animals has been
examined several times in vitro with various results show-
ing enhanced or diminished function (Kulseng et al, 1996;
Desfaits et al, 1998; Geerlings et al, 2000) (Sima et al, 1988;
Salvi et al, 1997; Tennenberg et al, 1999; Zykova et al, 2000).
To investigate the innate response of diabetic animals to
bacterial challenge in the dermis, we carried out in vivo
studies assessing the response at the cellular and molecular
levels. P. gingivalis was chosen since it is a Gram-negative
bacteria associated with both bite wounds and since it
causes tissue destruction in another connective tissue,
the gingiva (Williams, 1990; Goldstein, 1992; Brook, 2003).
These studies were carried out in db/db diabetic mice that
Figure1
A more pronounced inflammatory infiltrate is present in diabetic
compared with normoglycemic mice 3 d after inoculation of P.
gingivalis. P. gingivalis was inoculated subcutaneously into the scalp.
(A–D) diabetic mice (db/db); (E–H ), normoglycemic mice (db/þ ).
Results are shown for the center of the inflammatory infiltrate (A, B,
E, F) and 2 mm from the center to represent the peripheral area of the
infiltrate (C, D, G, H). Each photomicrograph is representative of six
mice in per group. Original magnification 7mm¼100 microns (A, E, C,
G) or 7mm¼ 50 microns (B, F, D, H).
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share many similarities with type 2 diabetes in humans.
They become frankly obese at a young age, develop
hyperglycemia and insulin resistance, and exhibit signs of
polyphagia, polydipsia, and polyuria (Coleman and Hum-
mel, 1974; Leiter et al, 1981).
A significant finding was that one day following P.
gingivalis inoculation, the inflammatory response was similar
in diabetic and control mice, whereas 3 d later inflammation
was downregulated in the controls but not diabetics. This
difference was not due to a deficit in bacterial killing in the
diabetic group since inoculation of fixed bacteria induced
a similar persistent inflammation (data not shown). At the
molecular level, prolonged inflammation was demonstrated
by persistent cytokine expression. The physiologic signifi-
cance of protracted TNF expression was shown when
prolonged expression of MCP-1 and MIP-2 was largely
reversed by specifically neutralizing TNF. These data are
consistent with our previous study using the same model
system, which demonstrated that a significant component of
the inflammatory response and bone resorption induced by
a relatively mild P. gingivalis infection was due to TNF-a
activity (Graves et al, 2001). Cytokine dysregulation asso-
ciated with diabetes could explain the more severe sequelae
to infection noted in diabetics compared with normal
individuals.
Studies reported here indicate that the local response to
bacterial infection in diabetes is characterized by prolonged
inflammation that can be reversed with TNF inhibitors.
Sustained cytokine expression and persistent inflammation
has been shown to occur in the late phase of wound healing
in diabetic mice (Wetzler et al, 2000). Additionally, it has
been shown that this prolonged inflammation in wound
healing is linked to the effect of advanced glycation
endproducts (Goova et al, 2001). Similarly, prolonged
expression of chemokines is thought to play a role in
diabetic complications that involve local inflammation
including diabetic retinopathy and nephropathy (Elner et al,
1995; Banba et al, 2000).
The underlying basis for TNF-a dysregulation in diabetics
could come from several sources. One possibility is that the
combined stimulation of bacterial infection and advanced
glycation end products leads to a more prolonged inflam-
matory response. In support of this, inhibition of advanced
glycation end products reduces the severity of periodontal
disease in a mouse model and is associated with a decrease
in the level of TNF-a expression (Lalla et al, 2000). An
alternative explanation is that diminished sensitivity to
Figure 2
An inflammatory infiltrate induced by P. gingivalis inoculation is
more persistent in diabetic compared with normoglycemic mice.
P. gingivalis was inoculated by subcutaneous injection into the scalp.
The degree of PMN infiltration was assessed at the center of the
inflammatory infiltrate and at its periphery in two H&E-stained sections
per mouse using a scale of 0 to 9. Results are shown as mean  SEM
of six mice per group. (A) One day following inoculation of 5  108
bacteria. (B) Three days following inoculation of 5  108 bacteria. (C)
Three days following inoculation of 1  108 bacteria. A significant
difference was noted between the diabetic and the control groups at
both the center and the periphery of the inflammatory infiltrate on day 3
for both doses of bacteria (po0.05). No difference was noted on day 1.
Figure3
Diabetes prolongs bacteria-induced expression of TNF-a in db/db
mice. P. gingivalis (5  108) was injected subcutaneously into the
scalp. Mice were euthanized at 0, 1 or 3 days. RNA was extracted from
the soft tissue followed by an RPA analysis. The density of each band
was quantified and normalized by the level of GAPDH expression in the
same lane. On day 3, there was a significant difference between the
diabetic and control group (po0.05).
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insulin combined with obesity and the tendency of adipose
cells to produce TNF-a leads to greater cytokine expres-
sion. This is indirectly supported by studies demonstrating
that medications used to treat type 2 diabetes, such as
thiazolidinediones and sulfonylureas, enhance sensitivity
to insulin and reduce TNF-a levels (Peraldi et al, 1997;
Desfaits et al, 1998; Sigrist et al, 2000). Regardless of the
underlying cause, studies presented here suggest that
diabetes modulates the response to infection by prolonging
the duration of TNF-a expression, which may disrupt cyto-
kine networks leading to more persistent inflammation and
tissue damage.
Materials and Methods
Mice Db/db mice on a C57BL/KSJ background and normogly-
cemic db/þ heterozygous littermates were purchased from the
Jackson Laboratory (Bar Harbor, Maine). Db/db mice develop
diabetes at 6–8 wk of age. Experiments were initiated when mice
were 10–11 wk old and diabetic for approximately 20 d. The
degree of hyperglycemia was similar among mice in the diabetic
group typically having glucose levels of 400–450 mg per dL.
Glycosylated hemoglobin levels were 10%–15% for db/db mice
and under 5% for normoglycemic littermates. For all data points,
n¼ 6. All procedures were approved by the Institutional Animal
Care and Use Committee.
Inoculation of bacteria Mice were anesthetized with ketamine (80
mg per kg) and xylazine (10 mg per kg). P. gingivalis was inoculated
adjacent to the periosteum at a point on the midline of the skull
located between the ears, which is reproducible and leads to an
inflammatory response close to the lamboid suture. P. gingivalis
strain 381 was streaked onto bovine heart infusion agar plates
and incubated in an anaerobic chamber of 10% CO2, 10% H2, and
80% N2 at 371C for 7 d, harvested during logarithmic growth, and
Figure 4
Diabetes prolongs bacteria-induced expression of MIP-2 and
MCP-1. P. gingivalis was injected subcutaneously in the scalp of db/
db or db/þ control mice. RNA was extracted from the soft tissue and
analyzed by RPA. The density of each band was quantified and
normalized according to the level of GAPDH expression in the same
lane. (A) MIP-2 expression; (B) MCP-1 expression. The difference
between the diabetic and control group was significant on day 3
(po0.05).
Figure5
TNF inhibition overcomes persistent inflammation induced by
bacteria in diabetic mice. Diabetic db/db mice were inoculated with P.
gingivalis and treated with Enbrel or vehicle alone, PBS. RNA was
extracted from soft tissue obtained 3 days following inoculation.
Inflammation was monitored by expression of MIP-2 and MCP-1 as
measured by the RNase protection assay. The density of each band
was quantified and normalized by GAPDH in the same lane. (A) MCP-1;
(B) MIP-2 expression. There was a significant difference between the
TNF inhibitor compared with the PBS-treated mice (po0.05).
90 NAGUIB ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
suspended in 50 mL of sterile PBS. Mice were inoculated with
1  108 or 5  108 bacteria.
Histologic analysis Following euthanization, the calvaria with
intact soft tissue was fixed for 48 h in cold 4% paraformaldehyde
and decalcified with cold Immunocal (Decal Corporation, Congers,
New York) for approximately 10 d, with solution changed every 2 d.
The specimens were washed with sucrose and frozen at 801C.
Frozen tissue was embedded in Histoprep (Fisher Scientific,
Pittsburgh, Pennsylvania). Five-micron sections were prepared
and stained with hematoxylin and eosin. The degree of inflamma-
tion was characterized in two areas, the area where the
inflammatory infiltrate was highest and approximately 2 mM on
each side of the center of the infiltrate, representing peripheral
inflammation. The following scale was used to measure the number
of PMNs at the center of the inflammatory infiltrate: 1, no PMNs; 3,
slight infiltrate; 5, moderate infiltrate; 7, severe infiltrate; and 9,
severe infiltrate with cell necrosis; PMN infiltration in the periphery
was: 0, no PMNs; 1, very slight infiltrate; 3, slight infiltrate in a thin
band; 5, slight infiltrate in a thick band; 7, moderate infiltrate in a thin
band; and 9, moderate infiltrate in a thick band. Two sections from
each specimen were examined. Two blinded investigators mea-
sured each section and the mean score was used in the analysis.
For statistical analysis the mouse was the unit of measurement.
Cytokine expression The scalps of mice were dissected from the
calvaria and immediately frozen in liquid nitrogen at 0, 1, and 3 days
following inoculation with P. gingivalis. Total RNA was extracted with
Trizol (Life Technologies, Rockville, Maryland) from pulverized frozen
tissue following the manufacturer’s instructions. The concentration
and integrity of the extracted RNA were verified by denaturing
agarose gel electrophoresis. Gene expression was measured by the
RNase protection assay. 32P-labeled riboprobes were incubated
with 12 mg of total RNA and then subjected to RNase digestion
using a kit from Pharmingen (BD Biosciences, Franklin Lakes, New
Jersey) following the manufacturer’s instructions. Following electro-
phoresis on a 0.6% polyacrylamide gel, radiolabeled bands were
visualized using a PhosphorImager (Biorad Laboratories, Hercules,
California), and optical density was measured with Image ProPlus
software (Media Cybernetics, Silver Spring, Maryland). Each value
was normalized by the value of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) in the same lane. The mean and standard
error from three separate RNase protection assays is shown,
expressed as the percent maximum divided by 100.
Injection of TNF inhibitor Db/db mice were treated by intraper-
itoneal injection of vehicle alone or Enbrel (150 mg), a specific TNF
inhibitor that contains the extracellular domain of TNF receptor-2
linked to the Fc region of IgG1, generously provided by the Amgen,
Inc., Thousand Oaks, CA. This was given 24 h prior to bacterial
inoculation, which was supplemented by local injection of vehi-
cle or inhibitor (10 mg) just prior to inoculation. The scalps of mice
were then dissected from the calvaria and immediately frozen in
liquid nitrogen. RNA extraction and RNase protection assay were
performed as described above.
Statistical analysis Significance was determined by one-way
analysis of variance with values of po0.05 considered to be
significant.
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